Correspondence 0000950170-23-035318 from Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Inc.
Date: July 28, 2023 · CIK: 0001671584 · Accession: 0000950170-23-035318

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-273067

Date

July 27, 2023

Author

Marvin L. White

Form

CORRESP

Company

Aptevo Therapeutics Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Mr. Daniel Crawford Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 File No. 333-273067

Dear Mr. Crawford:

Reference is made to our letter, filled as correspondence via EDGAR on July 26, 2023, in which we requested acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-273067) of Aptevo Therapeutics Inc. (the “Registration Statement”) for 5:30 p.m., Eastern Time, on July 27, 2023, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at such time and we hereby formally withdraw our request for acceleration of the effective date of July 27, 2023. Please contact our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704 if you have any questions regarding this matter.

Very truly yours,
Aptevo Therapeutics Inc.

Show Raw Text

CORRESP
1
filename1.htm

  CORRESP

  July 27, 2023

  VIA EDGAR

  United States Securities and Exchange Commission

  Division of Corporation Finance

  Office of Life Sciences

  100 F Street, N.E.

  Washington, D.C. 20549

  Attention: Mr. Daniel Crawford

  Re: Aptevo Therapeutics Inc.

  Registration Statement on Form S-1
File No. 333-273067

  Dear Mr. Crawford:

  Reference is made to our letter, filled as correspondence via EDGAR on July 26, 2023, in which we requested acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-273067) of Aptevo Therapeutics Inc. (the “Registration Statement”) for 5:30 p.m., Eastern Time, on July 27, 2023, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at such time and we hereby formally withdraw our request for acceleration of the effective date of July 27, 2023.  Please contact our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704 if you have any questions regarding this matter.

  Very truly yours,

  Aptevo Therapeutics Inc.

  By: /s/ Marvin L. White

  Marvin L. White

  President and Chief Executive Officer

    CC:

    SoYoung Kwon, Aptevo Therapeutics Inc.
Daphne Taylor, Aptevo Therapeutics Inc.
Sean M. Donahue, Paul Hastings LLP

SecProbe.io